In another presentation at ATTD, data was presented from a preliminary analysis of self-reported outcomes of people using the t:slim Insulin Pump. A subset of t:slim Pump users self-reported their HbA1c, a three-month average blood glucose measurement (n=289). t:slim Pump users who had previously used a different insulin pump (n=211) saw an HbA1c decrease of 0.2 percentage points (p< 0.001, average t:slim Pump use approximately 6 months). People who had never used an insulin pump before (n=78), reported an HbA1c decrease of 0.9 percentage points (p<0.001, average t:slim Pump use approximately 5 months).
These data were presented as part of the Tandem-sponsored symposium, Optimizing Insulin Pump Use through Human Factors Research, moderated by Dr. Timothy Bailey. Human Factors Research is a scientific discipline that uses evidence-based data to optimize a device or system to the intended user through iterative usability testing and design refinement. Tandem's t:slim Pump was one of the first insulin pumps to use extensive Human Factors Research in its development. It is the first insulin pump with a color touch screen, rechargeable battery, and USB-connectivity, and it holds up to 300 units of insulin.
About Tandem Diabetes Care, Inc. Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in San Diego, California.
Forward Looking StatementThis press release includes forward-looking statements relating to Tandem's t:slim® Insulin Pump, including the results and conclusions from research studies comparing the t:slim Pump to other currently marketed insulin pumps, and the properties and potential benefits of using the t:slim Pump as compared to multiple daily injections. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including: risks that current and past results of research studies may not be indicative of results of future research studies or of actual user experience; the potential that newer products that compete with the t:slim Pump, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the t:slim Pump obsolete or less desirable; Tandem's ability to manufacture products in commercial quantities at an acceptable cost and while maintaining quality standards; and other risks identified in Tandem's Registration Statement on Form S-1. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update any forward-looking statement in this press release.Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim and #tconnect. Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes. t:slim, t:connect and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc. Medtronic and Minimed are registered trademarks, and Revel is a trademark, of Medtronic, Inc.